Klacid I.V.

Clarithromycin, the active ingredient in Klacid I.V., is a macrolide antibiotic presented as an injectable solution for intravenous use. It treats a range of bacterial infections, including community‑acquired pneumonia, upper respiratory tract infections, skin and soft‑tissue infections, and Helicobacter pylori eradication, primarily in adult patients.

GNH USA supplies Klacid I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The product complies with EU marketing authorisation standards and is distributed under strict quality‑assured conditions, ensuring consistent potency and safety for clinical use.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections affecting the respiratory, skin and gastrointestinal systems. - Community‑acquired pneumonia: achieves clinical cure and bacterial eradication in adult patients. - Upper respiratory tract infections: reduces symptoms and clears the causative pathogens. - Skin and soft tissue infections: resolves infection and promotes tissue healing. - Mycobacterial infections: contributes to treatment regimens for certain non‑tuberculous mycobacteria. - Helicobacter pylori eradication: forms part of combination therapy to achieve bacterial eradication.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Taste disturbance

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions - QT interval prolongation leading to cardiac arrhythmias - Hepatic dysfunction, including hepatitis - Clostridioides difficile‑associated diarrhea

When using Klacid I.V., clinicians should consider several precautionary measures to ensure safe administration. - Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and use with caution. - Concomitant QT‑prolonging drugs: avoid co‑administration or monitor ECG closely. - Pregnancy Category B: prescribe only when potential benefit justifies potential risk. - Breastfeeding: caution advised as drug may be excreted in milk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Clarithromycin interacts with several medicines through metabolic pathways and cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may increase clarithromycin levels and toxicity. - Drugs that prolong QT interval (e.g., quinidine, sotalol): risk of serious arrhythmias. - Certain antiarrhythmics (e.g., amiodarone): can lead to additive cardiac effects.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Carbamazepine: may reduce clarithromycin concentrations, monitor efficacy. - Oral contraceptives: may decrease hormonal effectiveness, advise alternative contraception.